Summary of the announcement with a few more background details.
What is AlFluor™?
A new radiochemistry platform using 18F-aluminium fluoride (18F-AlF) for PET imaging.
Designed for flexible labeling of PSMA, and potentially NET and FAP ligands
Supports both central cyclotron production and kit-based “shake-and-inject” use
Why it matters:
Combines the high image quality of 18F with the practical convenience of 68Ga, offering clinicians:
Choice of isotope for same targeting agent
Better workflow fit across different clinical settings
Strategic Agreement:
Telix has partnered with Ghent University & Hospital for exclusive rights to [18F]AlF-PSMA-11, including:
Phase 3 trial data in 96 prostate cancer patients
Demonstrated diagnostic accuracy on par with Illuccix® and Gozellix® (~90% specificity)
Strong biodistribution and low off-target uptake
Next Steps:
Regulatory engagement for approval pathway
AlFluor™ to support Telix's broader PSMA-PET imaging agent portfolio
CEO Quote:
Telix aims to lead PSMA-PET imaging through innovation, flexibility, and meeting physician needs.
Summary of the announcement with a few more background...
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$24.92 |
Change
-0.080(0.32%) |
Mkt cap ! $8.429B | |||
| Open | High | Low | Value | Volume |
| $24.99 | $25.11 | $24.45 | $50.91M | 2.047M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 4292 | $24.90 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $24.95 | 123 | 1 |
View Market Depth
| Last trade - 16.10pm 20/06/2025 (20 minute delay) ? |
| TLX (ASX) Chart |